• Active, not recruiting

NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma

Updated: Sep 16

NCT03269136

MAGNETISMM-1

RRMM

MAGNETISMM1 elranatamab myeloma trial

NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma


Sponsor

Pfizer

 

ClinicalTrials.gov Identifier: NCT04649359

Official Title: A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF PF-06863135, A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)

First Posted : August 31, 2017

Click here for details on ClinicalTrials.gov


You don’t have to take on multiple myeloma alone | Pfizer Clinical Trials

 

Elranatamab

Elranatamab (Code C146860)

Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135

B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135

BCMA x CD3 Bispecific Antibody PF-06863135

BCMA-CD3 Bispecific Ab PF-06863135

Elranatamab

ELRANATAMAB

PF 06863135

PF-06863135

PF06863135

RN 613

RN-613

RN613

 

Drug: PF-06863135 monotherapy IV or SC

Drug: PF-06863135 + dexamethasone (Decadron)

Drug: PF-06863135 + lenalidomide (Revlimid)

Drug: PF-06863135 + pomalidomide (Pomalyst)

 

MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) TARGETED CD3-ENGAGING BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)

Abstract: S192

Type: Oral Presentation

Session title: T cell re-directing therapies in relapsed/refractory multiple myeloma

EHA Library. 06/09/21

Click here for details

 

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

Abstract 8006

2021 ASCO Annual Meeting

Click here for details

 

895 Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma

Hematology Disease Topics & Pathways:

Biological, Plasma Cell Disorders, Diseases, Therapies, Immunotherapy, Myeloid Malignancies

Monday, December 13, 2021: 6:15 PM

Click here for details

 

- Multiple Locations

- International Study

- Illinois: University of Chicago

- Iowa: University of Iowa Iowa city

- Massachusetts: Massachusetts General Hospital Boston

- New York: Memorial Sloan-Kettering Cancer Center New York

- North Carolina: Duke University Hospital Durham

- Texas: Baylor University Medical Center Dallas

 

Locations

United States, California

United States, Georgia

United States, Illinois

United States, Iowa

United States, Louisiana

United States, Massachusetts

United States, New Jersey

United States, New York

United States, North Carolina

United States, Tennessee

United States, Texas


Canada, Alberta

Canada, Ontario

Canada, Quebec

 

RELATED POSTS


MAGNETISMM-2

NCT04798586: Phase 1: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma - MAGNETISMM-2

Click here for details


MagnetisMM-3

NCT04649359: Phase 2: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma - MagnetisMM-3

Click here for details


MagnetisMM-4

NCT05090566: Phase 2: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM - MagnetisMM-4

Click here for details


MagnetisMM-5

NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex - MagnetisMM-5

Click here for details


MagnetisMM-7

NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7

Click here for details


MagnetisMM-8

NCT05228470: Phase 2: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM - MagnetisMM-8

Click here for details


MagnetisMM-9

NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9

Click here for details


NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Click here for details






Posts Archive